BNTC Benitec Biopharma Inc.
USHealthcareAs of 2026-07-10 16:00
Why BNTC matters now
Benitec Biopharma Inc. (BNTC) is a US stock in Healthcare. The latest InvestLog snapshot shows $13.42 with -0.45% on the session and $352.2M in market capitalization; recent performance reads 1-month +13.34% and YTD -9.80%.
The latest financial table shown here is Q3 2026, with revenue of $0.00, net income of $-11.9M, and EPS of $-0.24. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -6.5%.
The latest indexable market news headline is "Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $25.00; recent insider activity includes Friedman David Matthew filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.27
P/S
0.00
EV/EBITDA
-2.53
DCF Value
$2.67
FCF Yield
-6.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-34.8%
ROA
-26.1%
ROIC
-29.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $0.00 | $-11.9M | $-0.24 |
| Q2 2026 | $0.00 | $-11.8M | $-0.26 |
| Q1 2026 | $0.00 | $-9.0M | $-0.22 |
| Q4 2025 | $0.00 | $-16.1M | $-0.39 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$25.00
Target (Median)
$25.00
Target Range
$25.00 - $25.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.28
Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring human conditions. Its pipeline features BB-301, an adeno-associated virus (AAV) gene therapy aimed at treating oculopharyngeal muscular dystrophy, and BB-103, designed to combat chronic hepatitis B virus infection. Established in 1995, Benitec Biopharma's main operations are situated in Hayward, California.